Reaction

Recurrent Cancer reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,000 reports · 104 co-occurring drugs

As of the last recalculation, Recurrent Cancer appears in 4,000 FAERS reports alongside 104 co-occurring drug terms. The strongest observed disproportionality signal is NIRAPARIB (PRR 224.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Niraparib	774	224.8	232.9
Ado-Trastuzumab Emtansine	57	35.7	35.9
Imatinib Mesylate	132	25.4	25.6
Rucaparib	41	24.4	24.5
Olaparib	85	21.6	21.7
Temozolomide	77	19.4	19.4
Imatinib	56	16.7	16.8
Octreotide Acetate	96	16.7	16.7
Thiotepa	23	12.6	12.6
Lapatinib	35	11.8	11.9
Vismodegib	20	11.7	11.8
Pertuzumab	57	11.1	11.1
Trastuzumab	141	11.0	11.1
Anastrozole	74	10.7	10.7
Busulfan	30	10.0	10.0
Dabrafenib	40	10.0	10.0
Axicabtagene Ciloleucel	18	9.5	9.5
Trametinib	43	9.3	9.4
Capecitabine	150	8.8	8.8
Fulvestrant	52	8.3	8.3
Goserelin	21	8.2	8.2
Human Immunoglobulin G	32	8.1	8.1
Fludarabine Phosphate	60	8.0	8.1
Everolimus	77	8.0	8.0
Everolimus Tablets	23	7.2	7.2
Pazopanib Hydrochloride	37	7.2	7.2
Exemestane	29	7.1	7.1
Ifosfamide	28	6.8	6.8
Prochlorperazine Maleate	12	6.8	6.8
Letrozole	79	6.8	6.8
Etoposide	90	6.5	6.5
Pembrolizumab	124	6.3	6.3
Erlotinib Hydrochloride	15	6.3	6.3
Cytarabine	71	6.2	6.2
Paclitaxel (Aibumin-Bound)	94	6.1	6.1
Pancrelipase	44	6.0	6.0
Erlotinib	11	5.9	5.9
Anastrozole Tablets	24	5.8	5.9
Gefitinib	10	5.8	5.8
Heparin Sodium	15	5.7	5.7
Ribociclib	34	5.6	5.6
Gemcitabine Hydrochloride	56	5.6	5.6
Paclitaxel	103	5.5	5.5
Melphalan Hydrochloride	26	5.4	5.4
Nilotinib	30	5.3	5.3
Venetoclax	61	5.2	5.2
Dronabinol	8	5.2	5.2
Letrozole Tablets	47	5.1	5.1
Cyclophosphamide Injection, Solution	168	5.1	5.1
Cyclophosphamide	168	5.1	5.1
Cyclophosphamide For Injection	168	5.1	5.1
Doxorubicin	86	5.1	5.1
Brentuximab Vedotin	10	5.1	5.1
Gemcitabine	38	5.1	5.1
Bleomycin Sulfate	10	5.0	5.1
Prochlorperazine	26	4.9	4.9
Durvalumab	19	4.9	4.9
Melphalan	21	4.8	4.8
Acalabrutinib	11	4.7	4.7
Cisplatin	70	4.7	4.7
Carboplatin	112	4.7	4.7
Osimertinib	26	4.2	4.2
Bevacizumab	97	4.2	4.2
Dexamethasone Sodium Phosphate	8	4.1	4.1
Tramadol Hydrochloride	29	4.0	4.0
Doxorubicin Hydrochloride	24	3.8	3.8
Erythropoietin	15	3.8	3.8
Azacitidine	21	3.7	3.7
Docetaxel Anhydrous	46	3.6	3.6
Docetaxel	46	3.6	3.6
Bendamustine Hydrochloride	8	3.5	3.5
Azacitidine For	12	3.4	3.4
Fosaprepitant Dimeglumine	9	3.4	3.4
Filgrastim	23	3.2	3.2
Obinutuzumab	10	3.2	3.2
Cetuximab	19	3.2	3.2
Entecavir	7	3.1	3.1
Bendamustine Hcl	9	3.0	3.0
Fluorouracil	44	3.0	3.0
Fluorouracil Cream, 0.5%	43	3.0	3.0
Dasatinib	21	3.0	3.0
Aprepitant	10	2.8	2.8
Pemetrexed	11	2.7	2.7
Vincristine Sulfate	15	2.7	2.7
Lanreotide Acetate	4	2.7	2.7
Encorafenib	5	2.6	2.6
Ibrutinib	40	2.6	2.6
Blinatumomab	5	2.5	2.5
Palbociclib	41	2.2	2.3
Risankizumab-Rzaa	35	2.2	2.2
Abemaciclib	8	2.1	2.1
Pemetrexed Disodium	15	2.1	2.1
Irinotecan Hydrochloride	5	2.0	2.0
Sunitinib Malate	15	2.0	2.0
Pegfilgrastim	35	1.9	1.9
Carfilzomib	10	1.8	1.8
Eltrombopag Olamine	8	1.8	1.8
Alpelisib	3	1.8	1.8
Somatropin	25	1.8	1.8
Pomalidomide	34	1.7	1.7
Ixazomib	9	1.6	1.6
Polatuzumab Vedotin	3	1.6	1.6
Fam-Trastuzumab Deruxtecan-Nxki	3	1.5	1.5
Cabozantinib	12	1.3	1.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.